Topic

Gina Parry, National Account Manager, VAI

Articles

If telehealth is here to stay, how is the industry adjusting?

Keeping Up with Telehealth: Pharma’s Evolution 

Mitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations. 

FDA Inspection and Enforcement Developments During the COVID-19 Pandemic

With nearly 25 years of experience in driving strategy & commercialization efforts in Biotech & Pharma, with an exclusive focus in Life Sciences (LS) strategic planning and industry marketing efforts for enterprise software solutions, Ferdi Steinmann is responsible for the LS global industry strategy development at 

Ferdi Steinmann outlines a few supply chain lessons that all pharma companies can learn from the COVID-19 pandemic.

The Pharma Supply Chain Post-COVID-19: Key Lessons and Opportunities 

Heather Zenk, Senior Vice President, Strategic Global Sourcing at AmerisourceBergen  

Taking stock of evolving practices in protecting the supply chain amid the pandemic, including partnering and planning for what’s next.

The Pharma Supply Chain: Responding to COVID-19

Rob Besse is Vice President, Archbow Consulting.

It is vital to begin asking questions about your company’s DSCSA readiness and compliance, as well as that of your strategic partners, writes Rob Besse.

What You Need to Know about the Drug Supply Chain Security Act

MilliporeSigma's Robert McGuirk speaks with Pharma Exec about the role of supply chain robustness in helping to mitigate the risk of drug shortages

Tackling Drug Shortages through Robust Supply Chains

Coexisting with the DSCSA may hinder new legislative efforts.

Policy Sync-Up: The Drug Importation Conundrum

How to navigate the production and reimbursement intricacies of bringing regenerative medicines from bench to bedside.

High-Stakes Manufacturing: Mitigating the Risks

Tim Willis, is Director, Commercial Sales EMEA, at Dataminr, and Oliver Wack is Principal at Control Risks.

Tim Willis and Oliver Wack outline the role of alternative data in supply chain risk management, and the ancillary benefits that come from adopting such technology.

Real-Time Information across the Pharma Supply Chain

Pharm Exec’s annual look at what lies ahead for the biopharma industry in the coming months examines eight key trends that are seemingly at tipping points in their evolution and poised to shape the life sciences landscape in 2019.

8 Tipping Points: Pharm Exec’s 2019 Industry Forecast

The next generation of supply chain shows an increasing need for blockchain technology.

In Blockchain We Trust

How low-cost drugs can succeed in the specialty pharmacy channel.

The ‘Spare-No-Expense’ Alternative

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

Specialty Supply Chain Decisions

With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you? 

Blockchain 101 for Pharma Executives

Accenture and DHL Release Blockchain Report

Steve Cottrell assesses the risks of lapses in pharma's supply chain visibility and outlines what can be done to minimize them

Shining a Light on Supply Chain Visibility

IEEE Releases Findings from Blockchain Report

Pharma supply chain "needs to get out of its silos"

How a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost,
and with an unexpected workforce dividend to boot.

Going to the Edge

Pharm Exec sits down with AmerisourceBergen supply chain leader Peyton Howell to discuss the latest trends in pharmaceutical distribution, including company efforts to boost efficiency, reliability, and enhance its groundbreaking partnership with Walgreens Boots Alliance.